The menopause market, previously overlooked and underdiagnosed, is now experiencing a boom, with investments accelerating and market size projections reaching $15 billion to $25 billion by 2030, growing at 8%–10% annually. This growth is fueled by regulatory tailwinds, escalating awareness, and a rising demand for personalized midlife health solutions, particularly after 20 years of medical misunderstandings that stemmed from a controversial 2002 study on hormone therapy.
Investment in menopause-focused companies has seen approximately $1.7 billion deployed between 2020 and 2025, with funding events growing about 15% annually. Venture capital accounts for over 80% of these investments, primarily targeting technology-enabled platforms, especially in care delivery. Larger corporate transactions contribute significantly to invested dollars in pharmaceuticals and consumer health. The market has already produced a "unicorn-scale" company, indicating its potential for scalability and attracting multiple category leaders.
Despite the increased chatter and celebrity endorsements, demand for treatments still outstrips scientific advancements. While new drugs like Astellas Pharma's Veozah (approved in May for hot flashes) and Bayer's recently approved Lynkuet offer non-hormonal options, some have faced challenges, such as Veozah's FDA safety warning for liver complications and slower-than-expected sales. Hormone therapy, once controversial, is also seeing renewed interest as research suggests benefits for women under 60.
The market opportunity is global and substantial, with management consultants estimating potential ranging from $120 billion to $350 billion worldwide. This includes pharmaceuticals, care delivery, devices, diagnostics, consumer health, and employer solutions. Notably, approximately $1.8 billion in lost work time annually in the US is attributed to menopause, highlighting its economic impact. Employer benefits are expanding, with 25% of US employers offering dedicated menopause benefits in 2026, up from 4% in 2023, signaling a growing recognition of menopause as both a healthcare gap and a workforce issue. Companies like Midi Health, a virtual care clinic, have attracted significant investor dollars, including a $25 million Series A round led by Google Ventures, as women actively seek out solutions and expect better care access and outcomes.
